Therapeutic Noninvasive Brain Stimulation in Alzheimer’s Disease

Gonsalvez, Irene; Baror, Roey; Fried, Peter J.; Santarnecchi, Emiliano; Pascual‐Leone, Álvaro

doi:10.2174/1567205013666160930113907

Cited by 48 publications

(34 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A different, non-invasive yet still experimental in AD, research approach for neuromodulation is the targeting of neocortical regions relevant to AD pathophysiology-through the scalp by applying repetitive transcranial magnetic stimulation (rTMS) or weak currents via transcranial direct current stimulation (tDCS), in repeated daily sessions of stimulation [421]. Mechanisms of action are different, as rTMS makes cortical neurons to fire trans-synaptically [422], while tDCS shifts the level of their firing probability in a polarity-dependent manner [423].…”

Section: Contribution and Role Of Neuromodulationmentioning

confidence: 99%

“…Both stimulation techniques induce controllable excitatory or inhibitory after effects: high-frequency rTMS and anodal tDCS generally increase cortical excitability, while low-frequency rTMS and cathodal tDCS do the opposite [424, 425]; these effects are either local or involve the cortico-subcortical network to which the targeted region belongs [426]. In case of AD, the mere “stimulation” of a cortical target, even if prolonged for several daily sessions, does not help so much in preventing the decline of memory and other cognitive functions [421]. However, there are few controlled studies for rTMS in AD and even less for tDCS, for a total of a few dozens of patients treated so far [421].…”

Section: Contribution and Role Of Neuromodulationmentioning

confidence: 99%

“…In case of AD, the mere “stimulation” of a cortical target, even if prolonged for several daily sessions, does not help so much in preventing the decline of memory and other cognitive functions [421]. However, there are few controlled studies for rTMS in AD and even less for tDCS, for a total of a few dozens of patients treated so far [421]. What is emerging as a possible role for non-invasive neuromodulation is the coupling of stimulation with cognitive therapy, with the aim to promote plastic associative learning mechanisms to synergically improve the effects of cognitive rehabilitation only [427–429].…”

Section: Contribution and Role Of Neuromodulationmentioning

confidence: 99%

See 2 more Smart Citations

Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology

Hampel

Toschi

Babiloni

et al. 2018

JAD

Self Cite

123

113

View full text Add to dashboard Cite

The Precision Neurology development process implements systems theory with system biology and neurophysiology in a parallel, bidirectional research path: a combined hypothesis-driven investigation of systems dysfunction within distinct molecular, cellular and large-scale neural network systems in both animal models as well as through tests for the usefulness of these candidate dynamic systems biomarkers in different diseases and subgroups at different stages of pathophysiological progression. This translational research path is paralleled by an “omics”-based, hypothesis-free, exploratory research pathway, which will collect multimodal data from progressing asymptomatic, preclinical and clinical neurodegenerative disease (ND) populations, within the wide continuous biological and clinical spectrum of ND, applying high-throughput and high-content technologies combined with powerful computational and statistical modeling tools, aimed at identifying novel dysfunctional systems and predictive marker signatures associated with ND. The goals are to identify common biological denominators or differentiating classifiers across the continuum of ND during detectable stages of pathophysiological progression, characterize systems-based intermediate endophenotypes, validate multi-modal novel diagnostic systems biomarkers, and advance clinical intervention trial designs by utilizing systems-based intermediate endophenotypes and candidate surrogate markers. Achieving these goals is key to the ultimate development of early and effective individualized treatment of ND, such as Alzheimer’s disease (AD). The Alzheimer Precision Medicine Initiative (APMI) and cohort program (APMI-CP), as well as the Paris based core of the Sorbonne University Clinical Research Group “Alzheimer Precision Medicine” (GRC-APM) were recently launched to facilitate the passageway from conventional clinical diagnostic and drug development towards breakthrough innovation based on the investigation of the comprehensive biological nature of aging individuals. The APMI movement is gaining momentum to systematically apply both systems neurophysiology and systems biology in exploratory translational neuroscience research on ND.

show abstract

Section: Contribution and Role Of Neuromodulationmentioning

confidence: 99%

Section: Contribution and Role Of Neuromodulationmentioning

confidence: 99%

Section: Contribution and Role Of Neuromodulationmentioning

confidence: 99%

See 1 more Smart Citation

Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology

Hampel

Toschi

Babiloni

et al. 2018

JAD

Self Cite

123

113

View full text Add to dashboard Cite

show abstract

“…Location based on the functional involvement of cortical areas in relevant cortico-subcortical networks allows a much more specific and individualized treatment approach, which might be the best option in this disease [9, 24, 25]. Finally, the underlying mechanisms explaining the observed improvements (e.g.…”

Section: Introductionmentioning

confidence: 99%

Transcranial magnetic stimulation intervention in Alzheimer’s disease: a research proposal for a randomized controlled trial

et al. 2018

View full text Add to dashboard Cite

ObjectiveAlzheimer’s disease is a major health problem in our society. To date, pharmacological treatments have obtained poor results and there is a growing interest in finding non-pharmacological interventions for this disease. Transcranial magnetic stimulation (TMS) is a non-invasive technique that is able to induce changes in brain activity and long-term modifications in impaired neural networks, becoming a promising clinical intervention. Our goal is to study the benefit of individualized TMS targeting based on the patient’s functional connectivity (personalized targeting), and short duration TMS protocol, instead of current non-individualized and longer session approaches. A double blind randomized controlled trial will be conducted to assess the effects of TMS treatment immediately, 1 month, 3 months and 6 months after the end of the intervention. Fifty-four patients with a diagnosis of Alzheimer’s disease will be randomly allocated into experimental (active TMS), sham control, or conventional intervention control group. We will quantify changes in cognitive, functional, and emotional deficits in Alzheimer patients, as well as the functional connectivity changes induced by the TMS treatment.ResultsWe expect to demonstrate that personalized TMS intervention has a measurable positive impact in cognition, emotion, daily living activities and brain connectivity, thus representing a potential treatment for Alzheimer’s disease.Trial registration The trial has been prospectively registered at ClinicalTrials.gov, identifier NCT03121066. Date of registration: 04/19/2017

show abstract

“…Another device-based treatment reviewed by Gonsalvez, et al . [11] is Transcranial Magnetic Stimulation (TMS). TMS is currently approved for the treatment of depression.…”

mentioning

confidence: 99%